EDITORIAL

Eccentric viewing

What we don’t know about eccentric viewing
T W Raasch

The link between central scotomas, Troxler fading, and preferred retinal locus

Every clinician who has worked with patients with central scotomas has observed the difficulty those patients experience. Not only have they lost the ability to resolve fine detail, they also see nothing “straight ahead”. The resulting behaviour, most commonly called “eccentric viewing”, typically involves the development of a “pseudofovea”, or a preferred retinal locus (PRL). The use of a PRL is primarily an eye movement control issue: the individual must be able to place an object of interest on a particular fundus location. In addition to eye position control, however, successful use of an eccentric location must involve much more than just that. As Deruaz and colleagues have pointed out in this issue of BJO (p 461), higher level sensory processes are likely to be involved.

These authors have made the observation that some patients alternate between two retinal locations when deciphering a word. On further questioning, these patients reported that the displayed word was more distinct immediately after an eye movement. That phenomenon is attributed to the Troxler effect—that is, the fading of an object under stabilised conditions. This observation prompted the authors to conduct a laboratory experiment with normally sighted observers. This experiment is easy enough to replicate as a demonstration. Such a demonstration does seem to support the suggestion that Troxler fading might be experienced by those with central scotomas. We do not know, however, whether Troxler fading contributes to the development of multiple PRLs. As Deruaz et al suggest, saccades and other eye movements that occur naturally, even with a single PRL, probably prevent Troxler fading.

The efficient use of a PRL requires careful eye movement control. It must also require a shift of one’s attention to that location in the visual field. Consider a patient with two PRLs reading a full page of text. Words will fall on both PRLs simultaneously much of the time. In order to make sense of what is being viewed, that patient must be able to focus attention selectively on one or the other PRL. Without that ability, both regions of text would be equally salient.

An area that remains relatively unexplored is binocularity and PRLs. Most of what is known about PRL use applies to monocular viewing conditions. In an individual with bilateral central scotomas, how is the input from the two eyes integrated? Do PRLs tend to develop at corresponding retinal locations? Does a PRL tend to develop at a location that corresponds to a scotomatous area in the other eye? If PRLs develop in both eyes at non-corresponding locations, what happens under binocular conditions? Can both PRLs at non-corresponding points be used in a reading task? Can that person shift attention between those PRLs? Can this person experience confusion as the result of input from both PRLs? Is the input from one eye simply suppressed? We do not know the answers to those questions.

Eccentric viewing training is part of many comprehensive visual rehabilitation programmes. One wonders what should be the goal of eccentric viewing training. Does one reinforce to the trainee that the eccentric point is eccentric, preserving the normal oculocentric direction? Or does one attempt to replace the non-functioning fovea with that eccentric point? That is, should the goal be to shift the oculocentric direction to that eccentric point? If that is possible, it seems that would produce the most effective and effortless eccentric viewing behaviour possible. If the oculocentric direction shifts, however, is it a binocular shift, or does the shift occur independently (and perhaps unequally) for both eyes?

How one learns to view objects in the presence of a central scotoma is a complex issue. We have learned a great deal about this problem, but there is much more that we do not know. Perhaps we will learn whether training helps patients develop skills they otherwise would not develop, what type of training might be most effective, and in which patients training will be most effective. The growing number of visually impaired individuals will be better served when we have better answers to these questions.

Myopia

Myopia in Asia
P J Foster

An unexploded bomb

In this issue of the BJO (p 538), Saw and colleagues show that, after exclusion of syndrome associated and retinopathy of prematurity (ROP) related myopia, there was no identifiable link between birth weight and refractive error in later childhood. Low birth weight has been linked to adult risk of cardiovascular disease (CVD), hypertension, diabetes, and cancer.
trait is retained in adulthood. Fledelius examined 70 subjects with low birth weight (less than 2000 g) and 67 full term controls. The low birth weight-ocular size deficit remained an adult feature, even in seemingly normal eyes. There was also a parallel, permanent lack of “catch up” in height, head circumference, and other anthropometric factors.1

What marks this paper as interesting is the analytical method used by the investigators. Previous epidemiological studies of refractive error have used refraction as the sole end point.2,4 However, there is a growing recognition that the risk factors for, and natural history of, myopia and hypermetropia cannot be fully understood without recourse to ocular biometry.5,7 The inclusion of biometric data in the analysis has strengthened the authors’ abilities to examine the determinants of refractive error in this study of 1413 schoolchildren in Singapore. With the recognition that that bigger people have bigger eyes, without necessarily higher rates of myopia, the importance of correcting for co-determinants of axial dimensions, such as height, can be readily appreciated.5 Similarly, in the study of adult refractive error, changes in lens opacity are often accompanied by changes in refractive index, further complicating the modeling of risk factors.7

The size of the problem may parallel the rapid industrialisation and economic growth in China

The pathogenesis of diabetic retinopathy

M R Stanford

Sticky blood or sticky vessels, or both

There has been considerable interest in the past few years in the early pathological events that lead to vascular occlusion in diabetic retinopathy. The finding of increased leukostasis (leucocytes attached to the endothelial wall) is a common pathological event in both human disease1,2 and in experimental models.3,4 The heightened leucocyte/endothelial interaction induced by hyperglycaemia occurs very early in the diabetic process and, as a result, endothelial dysfunction and subsequent apoptosis occur. Although there is some reserve in terms of endothelial division and proliferation, this becomes exhausted with time, leading to the appearance of acellular capillary tubes, the pathological hallmark of disease.5 These tubes do not support blood flow and retinal ischaemia supervenes. Presumably there is pre-capillary arteriolar thrombosis due to the loss of the anti-thrombogenic endothelial lining, but pathological evidence for this is scant.6 The question arises as to whether this process is mediated by changes in leucocytes (sticky blood), changes in the endothelial surface (sticky vessels), or both.

Supporting the “sticky blood” hypothesis are the findings that leucocytes (particularly polymorphonuclear cells) are less deformable in diabetes,7 that there is upregulation of integrins (ligands for vascular adhesion molecules) on their surface,8 and that they adhere more strongly to cultured endothelial cells in vitro in both static assays and under conditions of flow.8 Furthermore, in vivo treatment with anti-integrin monoclonal antibodies experimentally markedly reduces leukostasis.9 Recent work has shown that the glycosylating enzyme, core 2 GlcNAc transferase, activity is upregulated in leucocytes derived from diabetic

REFERENCES


patients and that this upregulation positively correlates with the presence of established retinopathy. This enzyme causes post-translational modifications of the O-glycans on the cell membrane, some of which are molecules involved with endothelial interaction, and specific blockade of the phosphorylation of this enzyme abrogated the heightened leucocyte-endothelial interaction in vitro.\textsuperscript{5, 11}

Support for abnormalities in the endothelium (sticky vessel) comes from the immunohistochemical demonstration of increased adhesion molecule expression (particularly intercellular adhesion molecule-1, ICAM-1) on the cell surface in response to hyperglycaemia in both human\textsuperscript{1} and experimental models,\textsuperscript{5} and that the observed leucostasis in experimental models could be partially prevented by treatment with a monoclonal antibody against ICAM-1. Moreover, ICAM-1 knockout mice made diabetic do not develop the expected retinal vascular vasculature, is challenged in this issue of the BJO. In a carefully performed immunohistochemical study of human specimens, Hughes \textit{et al.} (p 566) show, in contrast with previous studies, that there is little difference in the expression of ICAM-1 between normal and diabetic retinas. Furthermore, their studies also show diffuse ICAM-1 staining of neural retina; this was increased in the diabetic specimens and correlated with local breakdown of the blood-retinal barrier. The reason for the disparity in their results and those of previous studies is comprehensively discussed and, although the diabetic history of their specimens is not known, the evidence is sufficiently forceful to prompt a re-evaluation of the subject. It seems likely that abnormalities of both blood and vessel wall contribute to the process of vaso-obliteration in diabetics although the relative importance of either still remains to be determined. Further work examining the role of reactive oxygen species in the promotion of a prothrombotic phenotype in the microvasculature and the contribution of leucocyte-platelet interactions, to microthrombus formation needs to be done. Understanding of the pathophysiological basis of diabetes is fundamental to the formulation of new treatments. Already, considerable interest has been shown in the use of anti-inflammatory drugs in the amelioration of diabetic retinopathy\textsuperscript{17} and early reports of the use of intravitreal steroids are promising. Certainly, there is now an increasing rationale for the use of specific protein kinase C inhibitors.\textsuperscript{11, 14}

Abnormalities of both blood and vessel wall probably contribute to the process of vaso-obliteration in diabetes.\textsuperscript{12, 13}

What occurs as a result of this leucocyte-endothelial interaction is not certain. Under normal physiological conditions, the interaction is necessary to allow the immune system to sample the microvascular environment with the leucocyte rapidly returning to the circulation if the correct sequential expression of adhesion molecules to allow firm tethering to the endothelial surface is not found. In diabetes, the reduced deformability and increased stiffness of the leucocyte may be sufficient to physically block capillary tubes.\textsuperscript{14} More likely is that the prolonged interaction leads to endothelial dysfunction and apoptosis, eventually leading to complete loss of the capillary lining.\textsuperscript{15, 16}

One of the principal hypotheses on which the above scenario is based—namely, that of increased adhesion molecule expression in the diabetic retinal vasculature, is challenged in this issue of the BJO. In a carefully performed immunohistochemical study of human specimens, Hughes \textit{et al.} (p 566) show, in contrast with previous studies, that there is little difference in the expression of ICAM-1 between normal and diabetic retinas. Furthermore, their studies also show diffuse ICAM-1 staining of neural retina; this was increased in the diabetic specimens and correlated with local breakdown of the blood-retinal barrier. The reason for the disparity in their results and those of previous studies is comprehensively discussed and, although the diabetic history of their specimens is not known, the evidence is sufficiently forceful to prompt a re-evaluation of the subject. It seems likely that abnormalities of both blood and vessel wall contribute to the process of vaso-obliteration in diabetics although the relative importance of either still remains to be determined. Further work examining the role of reactive oxygen species in the promotion of a prothrombotic phenotype in the microvasculature and the contribution of leucocyte-platelet interactions, to microthrombus formation needs to be done. Understanding of the pathophysiological basis of diabetes is fundamental to the formulation of new treatments. Already, considerable interest has been shown in the use of anti-inflammatory drugs in the amelioration of diabetic retinopathy\textsuperscript{17} and early reports of the use of intravitreal steroids are promising. Certainly, there is now an increasing rationale for the use of specific protein kinase C inhibitors.\textsuperscript{11, 14}

Current advances in knowledge of the pathology of the disease are likely to throw up further candidates in the near future.


\textbf{Author’s affiliation}

M R Stanford, Medical Eye Unit, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK; miles.stanford@kcl.ac.uk

\textbf{REFERENCES}


The pathogenesis of diabetic retinopathy

M R Stanford

doi: 10.1136/bjo.2003.031443

Updated information and services can be found at:
http://bjo.bmj.com/content/88/4/444

These include:

References
This article cites 19 articles, 9 of which you can access for free at:
http://bjo.bmj.com/content/88/4/444#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Retina (1608)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/